Xilio Therapeutics Presents Promising Initial Data for Vilastobart (XTX101) in Combination with Atezolizumab at ASCO GI 2025
Xilio Therapeutics reveals initial data on vilastobart (XTX101) with atezolizumab for metastatic MSS colorectal cancer at ASCO GI 2025.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Xilio Therapeutics shared encouraging initial Phase 2 data for its investigational anti-CTLA-4 monoclonal antibody, vilastobart (XTX101), in combination with atezolizumab (Tecentriq®). The trial evaluated the combination in metastatic microsatellite stable colorectal cancer (MSS CRC), traditionally resistant to immunotherapy. Highlights include a 27% objective response rate (ORR) in patients without liver metastases, with confirmed partial responses and significant biomarker reductions.
The combination therapy was well-tolerated, showing low immune-related adverse events (irAEs) and promising safety, underscoring its potential for broader tumor applications. Xilio plans further updates mid-2025 and seeks partnerships for expanded development.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion